Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Illumina, Inc. stock logo
ILMN
Illumina
$150.17
+3.4%
$132.17
$78.79
$155.53
$21.97B1.421.67 million shs1.89 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$47.61
+1.2%
$50.47
$22.28
$59.55
$18.66B1.057.77 million shs3.59 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Illumina, Inc. stock logo
ILMN
Illumina
+0.57%+2.48%+13.57%+19.17%+80.70%
Moderna, Inc. stock logo
MRNA
Moderna
+0.32%+2.87%-7.29%-8.45%+79.09%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Illumina, Inc. stock logo
ILMN
Illumina
$150.17
+3.4%
$132.17
$78.79
$155.53
$21.97B1.421.67 million shs1.89 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$47.61
+1.2%
$50.47
$22.28
$59.55
$18.66B1.057.77 million shs3.59 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Illumina, Inc. stock logo
ILMN
Illumina
+0.57%+2.48%+13.57%+19.17%+80.70%
Moderna, Inc. stock logo
MRNA
Moderna
+0.32%+2.87%-7.29%-8.45%+79.09%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Illumina, Inc. stock logo
ILMN
Illumina
2.28
Hold$137.75-8.27% Downside
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-24.95% Downside

Current Analyst Ratings Breakdown

Latest ILMN and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingNeutral
5/14/2026
Illumina, Inc. stock logo
ILMN
Illumina
Initiated CoverageOutperform$170.00
5/14/2026
Illumina, Inc. stock logo
ILMN
Illumina
UpgradeModerate Buy
5/14/2026
Illumina, Inc. stock logo
ILMN
Illumina
UpgradeNeutralOutperform$155.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/4/2026
Illumina, Inc. stock logo
ILMN
Illumina
Boost Price TargetSell$80.00 ➝ $95.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$33.00
5/1/2026
Illumina, Inc. stock logo
ILMN
Illumina
Reiterated RatingOutperform
5/1/2026
Illumina, Inc. stock logo
ILMN
Illumina
Lower Price TargetHold$150.00 ➝ $140.00
(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Illumina, Inc. stock logo
ILMN
Illumina
$4.34B5.23$6.94 per share21.63$17.69 per share8.49
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B9.72N/AN/A$18.67 per share2.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Illumina, Inc. stock logo
ILMN
Illumina
$850M$5.5027.3025.542.4019.42%31.01%12.22%7/30/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)

Latest ILMN and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/30/2026Q1 2026
Illumina, Inc. stock logo
ILMN
Illumina
$1.05$1.15+$0.10$0.87$1.07 billion$1.09 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Illumina, Inc. stock logo
ILMN
Illumina
0.56
1.75
1.36
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35

Institutional Ownership

CompanyInstitutional Ownership
Illumina, Inc. stock logo
ILMN
Illumina
89.42%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Illumina, Inc. stock logo
ILMN
Illumina
2.90%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Illumina, Inc. stock logo
ILMN
Illumina
8,650151.30 million146.91 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable

Recent News About These Companies

Moderna’s mRNA flu shot to get FDA review
Noubar Afeyan Sells 9,263 Shares of Moderna (NASDAQ:MRNA) Stock
James Mock Joins Moderna as Chief Financial Officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Illumina stock logo

Illumina NASDAQ:ILMN

$150.17 +4.94 (+3.40%)
Closing price 04:00 PM Eastern
Extended Trading
$150.10 -0.07 (-0.05%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$47.61 +0.58 (+1.23%)
Closing price 04:00 PM Eastern
Extended Trading
$47.85 +0.24 (+0.51%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.